Research News
Get the latest in Alzheimer’s screening and treatments.
A BrightFocus-funded scientist is investigating a novel imaging tool that could be used to find treatable blood clots in the brain and slow the progression of Alzheimer’s disease.
Students and senior Alzheimer’s researchers gathered in Chicago for an immersive workshop hosted by BrightFocus Foundation.
"It's never too early in life or too late in life to reduce risk for dementia,” says Dr. Quincy Samus, a member of the Lancet Standing Commission on Dementia Prevention, Intervention, and Care. Learn more about two new ways to do so.
Can controlling blood pressure curb mid-life Alzheimer’s risk? A BrightFocus-funded scientist investigates.
The Alzheimer’s risk gene APOE4 puts women at greater risk for Alzheimer’s disease than men. New research suggests this may be caused by an interaction between blood and brain immune cells that appears before any cognitive symptoms.
Alzheimer’s Disease Research, a BrightFocus Foundation program, was on the ground at the 2024 Alzheimer’s Association International Conference (AAIC) in Philadelphia to share insights on the latest research and foster scientific collaboration. Catch up on a few of the top headlines from AAIC.
A new BrightFocus-funded study of cognitively healthy 100-year-olds sheds light on genetic characteristics that protect the brain.
Another disease-modifying Alzheimer's therapy hits the market.
On June 10, the Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted that Eli Lilly’s Alzheimer’s drug, donanemab, is effective for treating early symptomatic Alzheimer’s disease.
